With the approval of Elunate (fruquintinib), China not only has a promising new option for colorectal cancer (CRC), a disease diagnosed in around 380,000 new Chinese people each year.
The country can also boast that the approval is evidence of the increasing strength of its biopharma industry as Elunate is the first cancer drug to be unconditionally approved that was discovered and developed in China.
"This is the result of over a dozen years of steadfast commitment by Chi-Med in research and development in China’s emerging biotech ecosystem"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze